miR-544a在结直肠癌组织中的表达及其意义

doi:10.3969/j.issn.1004-616x.2024.02.007

Abstract

Abstract: OBJECTIVE： To explore expression level and clinical prognostic value of microRNA-544a (miR-544a) in tissues of colorectal cancer patients. METHODS：From January 2016 to February 2019， 150 patients with colorectal cancer were selected. Real time fluorescence quantitative PCR was used to detect expression levels of miR-544a in tissues， and immunohistochemistry was used to detect the expression of Ki67，CD4，and CD8 in tissues. Mann Whitney U-test，chi square test，and Fisher′s exact test were used to analyze relationships between miR-544a expression level in cancer tissue and clinical pathological indicators of patients. Univariate and multivariate Cox regressions were used to analyze factors affecting the prognosis of colorectal cancer. The Kaplan-Meier method was used to analyze relationships between expression levels of miR-544a in tissues and disease-free survival (DFS) and overall survival (OS) of patients. RESULTS： The relative expression level of miR-544a in colorectal cancer tissue (1.85±0.15) was significantly higher than that in the adjacent normal tissues (1.06 ± 0.21) (P<0.01). The expression level of miR-544a was related to the incidence of peripheral nerve invasion，T staging，and N staging (all P<0.01)，while the high expression group of miR-544a had a higher incidence of nerve invasion and a later T and N staging. The immunohistochemical results showed that the Ki67 score of the miR-544a high expression group was 120.2±33.7，while the Ki67 score of the low expression group was 112.4±40.8，with no significant difference between the two groups (P> 0.05). The CD4 and CD8 scores of patients in the miR-544a high expression group were 15.5±5.3 and 24.8± 7.6， respectively， lower than those in the miR-544a low expression group (21.3 ± 7.2 and 29.6 ± 8.9， respectively)， with statistically significant differences (all P<0.05). Univariate and multivariate COX regression showed significant correlations between tumor N，M staging，and miR-544a expression levels and postoperative DFS and OS in CRC patients (all P<0.01). CONCLUSION： Upregulation of miR-544a expression in colorectal cancer tissue may be associated with delayed N and M stagings in colorectal cancer patients，and miR-544a may be a potential biomarker for immunotherapy efficacy.

Key words: colorectal cancer, miRNA, miR-544a, prognosis, tumor biomarker

CLC Number:

R735.3

TONG Jing, WANG Dan. Expression and significance of miR-544a in patients with colorectal cancer[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(2): 124-128,137.

References

[1] ZHENG R, ZHANG S W, ZENG H, et al. Cancer incidence and mortality in China, 2016[J]. J Nation Cancer Center, 2022, 2(1):1-9.
[2] KOULOURIS A, TSAGKARIS C, MESSARITAKIS I, et al. Resectable colorectal cancer:current perceptions on the correlation of recurrence risk, microbiota and detection of genetic mutations in liquid biopsies[J]. Cancers, 2021, 13(14):3522.
[3] IMAI K, BENITEZ C C, ALLARD M A, et al. Impact of surgical treatment for recurrence after 2-stage hepatectomy for colorectal liver metastases, on patient outcome[J]. Ann Surg, 2019, 269(2):322-330.
[4] HE B X, ZHAO Z Y, CAI Q D, et al. miRNA-based biomarkers, therapies, and resistance in cancer[J]. Int J Biol Sci, 2020, 16(14):2628-2647.
[5] ZHANG N, HU X Y, DU Y N, et al. The role of miRNAs in colorectal cancer progression and chemoradiotherapy[J]. Biomed Pharmacother, 2021, 134:111099.
[6] AZARI H, KARIMI E, SHEKARI M, et al. Construction of a lncRNA-miRNA-mRNA network to determine the key regulators of the Th1/Th2 imbalance in multiple sclerosis[J]. Epigenomics, 2021, 13(22):1797-1815.
[7] MA X M, MA T, CHANG L, et al. Correlation between miRNA-124, miRNA-544a, and TNF-α levels in acute spinal cord injury[J]. Spinal Cord, 2022, 60(9):779-783.
[8] HE Q R, ZHAO L N, LIU Y H, et al. Circ-SHKBP1 regulates the angiogenesis of U87 glioma-exposed endothelial cells through miR-544a/FOXP1 and miR-379/FOXP2 pathways[J]. Mol Ther Nucleic Acids, 2018, 10:331-348.
[9] LU P W, GU Y T, LI L, et al. miR-544a promotes breast cancer cell migration and invasion reducing cadherin 1 expression[J]. Oncol Res, 2016, 23(4):165-170.
[10] MO X M, ZHANG F H, LIANG H, et al. miR-544a promotes the invasion of lung cancer cells by targeting cadherina 1 in vitro[J]. Onco Targets Ther, 2014, 7:895-900.
[11] YANAKA Y, MURAMATSU T, UETAKE H, et al. miR-544a induces epithelial-mesenchymal transition through the activation of WNT signaling pathway in gastric cancer[J]. Carcinogenesis, 2015, 36(11):1363-1371.
[12] ZHENG W P, MENG F L, WANG L Y. miR-544a Stimulates endometrial carcinoma growth via targeted inhibition of reversion-inducing cysteine-rich protein with Kazal motifs[J]. Mol Cell Probes, 2020, 53:101572.
[13] SUN S F, SU C Y, ZHU Y X, et al. microRNA-544a regulates migration and invasion in colorectal cancer cells via regulation of homeobox A10[J]. Dig Dis Sci, 2016, 61(9):2535-2544.
[14] ZHANG L F, LIU L Y, LI X. miR-526b-3p mediates doxorubicin-induced cardiotoxicity by targeting STAT3 to inactivate VEGFA[J]. Biomed Pharmacother, 2020, 123:109751.
[15] PIERCEALL W E, WOLFE M, SUSCHAK J, et al. Strategies for H-score normalization of preanalytical technical variables with potential utility to immunohistochemical-based biomarker quantitation in therapeutic response diagnostics[J]. Anal Cell Pathol (Amst), 2011, 34(3):159-168.
[16] MESSERSMITH W A. NCCN guidelines updates:management of metastatic colorectal cancer[J]. J Natl Compr Cancer Netw, 2019, 17(5.5):599-601.
[17] PAIJENS S T, VLEDDER A, DE BRUYN M, et al. Tumorinfiltrating lymphocytes in the immunotherapy era[J]. Cell Mol Immunol, 2021, 18(4):842-859.
[18] OSTROUMOV D, FEKETE-DRIMUSZ N, SABOROWSKI M, et al. CD4 and CD8 T lymphocyte interplay in controlling tumor growth[J]. Cell Mol Life Sci, 2018, 75(4):689-713.

Expression and significance of miR-544a in patients with colorectal cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	FU Yongqing, XU Sanhui, ZHAO Yan, WANG Lili. Relationships between SPP1, DEC1, C1QTNF6 and clinicopathologic outcomes of oral squamous cell carcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(2): 107-111,117.
[2]	XUE Song, HU Jiahai, DONG Xiangning. Expression of PGAM5 and its association with clinicopathologic characteristics in pancreatic cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(1): 29-34.
[3]	WANG Kefang, CHEN Yu, WU Chenyu, LIU Mei, WANG Lijie, TIAN Jianguang, ZHOU Xiaohui, XU Lan. Clinicopathological roles of IL-17A and estrogen receptors α, β in epithelial ovarian cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(1): 42-47.
[4]	ZHU Wenbiao, QIU bo, XIE Shoucheng, XIAO Huanqin, LIU Gaomin. Expression and clinical significance of transmembrane protein 79 in hepatocellular carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(6): 426-430.
[5]	HE Guangsi, WEI Jie, ZHANG Jian. Usefulness for combined detection of serum miRNA-183 and carbohydrate antigen 199 in the diagnosis and prognosis of gastric cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(6): 457-461,466.
[6]	YANG Shangying, HUANG Mingxiang, XU Dexin, LIU Jiafu, CHEN Xinfu. Expression of DNAJB4 and association with immune infiltration and prognosis in non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(6): 467-472.
[7]	GUO Wenjing, DENG Hui, SONG Ping, ZHANG Mengxian. Expression and biological functions of TGFBI in glioma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(5): 341-348.
[8]	WEI Laifeng, HONG Chaoqun, CHEN Liuyi, XU Yiwei, WU Fangcai. Prognostic value of nomogram of laboratory inflammation-related indicators in tongue squamous cell carcinoma patients with surgery [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(5): 366-373.
[9]	YANG Chengqing, CUI Yonghui, ZHENG Ziheng. Expression and clinical significance of miR-653-5p in colon cancer patients [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(4): 261-265.
[10]	LIU Ruixue, ZHANG Liwei. Expression and significance of AMPK esophageal squamous cell carcinoma among Kazakhs [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(4): 285-291.
[11]	HUANG Mengpan, WANG Xuehong, LU Yongfu. Expression and clinical significance of TNF-α and FOXA2 in patients with colorectal cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(4): 296-301,324.
[12]	WANG Na, WANG Ping, HE Yijia, ZENG Jing, HAN Congling, WANG Sirui, XUAN Xiaoyan. Bioinformatic analysis of immune cell infiltration and tumor mutation burden in colorectal cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(3): 172-177.
[13]	LIU Ying, WANG Rui, GUO Xiao, DONG Lüli, ZHANG Yan, ZHAO Yinhuan, DU Yun. Relationships between DNA ploidy abnormality and EGFR mutation in pleural effusions, and their effects on prognosis of lung adenocarcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(3): 178-182,186.
[14]	WANG Ping, WANG Huayong, WANG Hao, LEI Dajun. Expression of miR-193a and miR-21-5p in serum exosomes from osteosarcoma patients and their clinical values [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(3): 197-201.
[15]	HUANG Lidan, WU Yueming, WANG Yadi, TAN Qi. Relationships between VEGF-A protein expression and EGFR mutation in patients with lung adenocarcinomas and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(2): 116-120.